IP Library Granted Patent US 12,005,042
Granted Patent B2
US 12,005,042 · App. 17/746,032 · Granted Jun 11, 2024

Rescue treatment of post operative nausea and vomiting

Inventors: Julian Clive Gilbert (Cambridge, GB); Robert William Gristwood (Cambridge, GB); Gabriel Fox (Cambridge, GB)
Assignee: Acacia Pharma Ltd.
A61K31/40A61K9/0019A61K31/4178A61K31/438A61K31/439A61K31/496A61K31/5377A61K31/573A61P1/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,005,042
App. No.
17/746,032
Granted
Jun 11, 2024
Kind
B2
Abstract

Amisulpride is useful in the treatment of postoperative nausea and/or vomiting in a patient, wherein the patient has already been administered a prophylaxis drug for postoperative nausea and/or vomiting, and wherein the dose of amisulpride is 7.5 to 15 mg.

Claims (17)

1. A method for treating postoperative nausea and/or vomiting (PONV) in a patient, comprising administering to the patient amisulpride at a dose of 9.5 mg to 10.5 mg, wherein the patient has been administered a non-amisulpride prophylaxis drug prior to surgery, and wherein the amisulpride is administered by IV infusion over a time period of from about 20 seconds up to about 20 minutes.

2. The method of claim 1 , wherein the prophylaxis drug is not a dopamine-2 (D 2 ) antagonist.

3. The method of claim 1 , wherein the prophylaxis drug is an anti-emetic selected from a 5HT 3 -antagonist, a corticosteroid, an anti-histamine (H1), an anti-cholinergic, a H 2 -antagonist and a NK 1 -antagonist.

4. The method of claim 1 , wherein the amisulpride is administered in combination with another anti-emetic, either sequentially or simultaneously.

5. The method of claim 4 , wherein the another anti-emetic is a 5HT 3 antagonist, an NK 1 antagonist or a steroid.

6. The method of claim 5 , wherein the another anti-emetic is dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant or rolapitant.

7. The method of claim 1 , wherein the amisulpride is substantially in the form of a racemate.

8. The method of claim 1 , wherein the amisulpride is administered within 1 hour following a first emetic episode and/or following a first nausea episode.

9. The method of claim 8 , wherein the amisulpride is administered within 30 minutes following the first emetic episode and/or following the first nausea episode.

10. The method of claim 9 , wherein the amisulpride is administered within 15 minutes following the first emetic episode and/or following the first nausea episode.

11. The method of claim 1 , wherein the amisulpride is administered by IV infusion over about 1 to 15 minutes.

12. The method of claim 11 , wherein the amisulpride is administered by IV infusion over about 1 to 10 minutes.

13. The method of claim 11 , wherein the amisulpride is administered by IV infusion over about 1 to 5 minutes.

14. The method of claim 11 , wherein the amisulpride is administered by IV infusion over about 1 to 2 minutes.

15. The method of claim 1 , wherein the amisulpride is administered at a dose of 10 mg.

16. The method of claim 1 , wherein the amisulpride is administered as a single daily dose.

17. A method for treating postoperative nausea and/or vomiting (PONV) in a patient, comprising administering to the patient racemic amisulpride at a dose of 10 mg, wherein the patient has been administered a non-amisulpride prophylaxis drug prior to surgery, and wherein the racemic amisulpride is administered by IV infusion over a time period of from about 20 seconds up to about 20 minutes.

Assignments (5)
SECURITY INTEREST Recorded Apr 27, 2026
From: LXO IRELAND DESIGNATED ACTIVITY COMPANY
To: KROLL TRUSTEE SERVICES LIMITED, AS SECURITY AGENT
Reel/Frame 074483/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2026
From: ACACIA PHARMA LIMITED; ACACIA PHARMA, INC.; EAGLE PHARMACEUTICALS, INC.
To: LXO IRELAND DESIGNATED ACTIVITY COMPANY; LXO US, INC.
Reel/Frame 073967/0303 →
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ACACIA PHARMA LIMITED
Reel/Frame 070698/0351 →
SECURITY INTEREST Recorded Oct 11, 2024
From: ACACIA PHARMA LIMITED
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 068873/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2022
From: GILBERT, JULIAN CLIVE; GRISTWOOD, ROBERT WILLIAM; FOX, GABRIEL
To: ACACIA PHARMA LTD
Reel/Frame 059930/0921 →
Priority Claims (1)
GB 1702250 · Feb 10, 2017 · national
Continuity (2)
Continuation 16485008
Related Publication 20230100786A1 · Mar 30, 2023
Cited By (1)
US 12,329,740